Search Within

Pedram Razavi

  1. "Early Drug Development Service"
Formats
  1. Journal Article (14)
  2. Meeting Abstract (10)
  3. Research Letter (1)
Groups
  1. Breast Medicine Service (25)
  2. Department of Medicine (25)
  3. Early Drug Development Service (25)
  4. Solid Tumor Oncology Division (25)
  5. Weinberg Fellows (25)
  6. GSK Faculty (24)

More Groups

People
  1. David Hyman (23)
  2. Michael Berger (14)
  3. Marc Ladanyi (13)
  4. David Solit (12)
  5. Jose Baselga (12)
  6. Sarat Chandarlapaty (12)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (2)
  4. 2020 (7)
  5. 2019 (5)
  6. 2018 (4)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. Cancer Research (4)
  3. Nature Medicine (3)
  4. Cancer Discovery (2)
  5. Journal of Molecular Diagnostics (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. American Society of Clinical Oncology (6)
  3. Nature Publishing Group (5)
  4. Elsevier Science, Inc. (2)
  5. American Association for the Advancement of Science (1)
  6. American Medical Association (1)

More Publishers

Results (25)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer
    Meeting Abstract

    Marra, A.; Selenica, P.; Zhu, Y.; Safonov, A.; Razavi, P.; Roulston, A.; Koehler, M.; Curigliano, G.; Ross, D. S.; Weigelt, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor-positive breast cancer
    Meeting Abstract

    Lacouture, M. E.; Pan, A.; Dranitsaris, G.; Harris, U.; Chandarlapaty, S.; Dang, C. T.; Gajria, D.; Gordon, A.; Iyengar, N. M.; Robson, M. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Utility of serial cfDNA NGS for prospective genomic analysis of patients on a phase I basket study
    Journal Article

    Smyth, L. M.; Reichel, J. B.; Tang, J.; Patel, J. A. A.; Meng, F.; Selcuklu, D. S.; Houck-Loomis, B.; You, D.; Samoila, A.; Schiavon, G.; more...
    JCO Precision Oncology (2021)

    Fulltext@MSK | Save
  • Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
    Journal Article

    Smyth, L. M.; Batist, G.; Meric-Bernstam, F.; Kabos, P.; Spanggaard, I.; Lluch, A.; Jhaveri, K.; Varga, A.; Wong, A.; Schram, A. M.; more...
    npj Breast Cancer (2021)

    Fulltext@MSK | Save
  • The utility of plasma ctDNA for detection of KRAS G12C and other mutations in lung cancers
    Meeting Abstract

    Murciano-Goroff, Y. R.; Arbour, K. C.; Offin, M. D.; Tu, H. Y. Y.; Lebow, E. S.; Shaffer, T. S.; Bertucci, C.; Hosseini, S. A.; Garg, K.; Lim, L. P.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer
    Meeting Abstract

    Liu, B.; Ross, D. S.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients
    Journal Article

    Ross, D. S.; Liu, B.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Characterizing KRAS G12C and other mutations in plasma ctDNA from patients with lung cancer
    Meeting Abstract

    Murciano-Goroff, Y. R.; Lebow, E. S.; Tu, H. Y.; Li, M.; Lim, L. P.; Arbour, K. C.; Travis, W.; Solit, D. B.; Ladanyi, M.; Jones, D. R.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer
    Meeting Abstract

    Smyth, L. M.; Batist, G.; Meric-Bernstam, F.; Kabos, P.; Spanggaard, I.; Lluch, A.; Schram, A.; Varga, A.; Wong, A.; Ambrose, H.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers
    Journal Article

    Li, B. T.; Michelini, F.; Misale, S.; Cocco, E.; Baldino, L.; Cai, Y.; Shifman, S.; Tu, H. Y.; Myers, M. L.; Xu, C.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save